Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. [electronic resource]
Producer: 20090514Description: 1999-2006 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Breast Neoplasms -- drug therapy
- Capecitabine
- Chemotherapy, Adjuvant
- Deoxycytidine -- administration & dosage
- Disease Progression
- Female
- Fluorouracil -- administration & dosage
- Follow-Up Studies
- Humans
- Immunoenzyme Techniques
- International Agencies
- Middle Aged
- Neoplasm Staging
- Prognosis
- Receptor, ErbB-2 -- metabolism
- Risk Factors
- Survival Rate
- Time Factors
- Trastuzumab
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.